Skip to main content
main-content

Medicine Matters oncology

The Chinese University of Hong Kong, Hong Kong

New Content Item

Tony Mok was trained at the University of Alberta and subsequently completed a fellowship in medical oncology at the Princess Margaret Hospital. After working as a community oncologist in Toronto for seven years, he returned to Hong Kong in 1996 to pursue an academic career.

Professor Mok is the Li Shu Fan Medical Foundation Named Professor of Clinical Oncology and Chairman of Clinical Oncology at The Chinese University of Hong Kong. His main research interest focuses on biomarker and molecular-targeted therapy in lung cancer. He co-founded the Lung Cancer Research Group, and has led a number of important multinational clinical trials, which include the IPASS (IRESSA Pan-Asia Study), a landmark study that established the role of first-line gefitinib in patients with EGFR mutations.

Professor Mok has contributed to over 200 articles in international peer-reviewed journals, including The New England Journal of Medicine, Science, The Lancet and Journal of Clinical Oncology, and has also contributed to multiple editorials and textbooks. He is also active and experienced in serving academic societies. He is the Past President of the International Association for the Study of Lung Cancer (IASLC), Past Chair of the American Society of Clinical Oncology (ASCO) International Affairs Committee, a member of the ASCO Publications Committee and Vice Secretary of the Chinese Society of Clinical Oncology (CSCO).

He is closely affiliated with the oncology community in China and has received an Honorary Professorship at Guang Dong Province People’s Hospital, Guest Professorship at Peking University School of Oncology, Visiting Professorship at Shanghai Jiao Tong University and West China School of Medicine/West China Hospital, Sichuan University. He is an Editor on thoracic oncology for the Journal of Clinical Oncology. He has also authored eight books in Chinese and hosted three television series in Hong Kong.